A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

Name: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
License: Public Domain

Sinocelltech Ltd.

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

covid-19, sars-cov-2 infection

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 245579
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.